A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 609,700 shares of SPRB stock, worth $243,880. This represents 0.0% of its overall portfolio holdings.

Number of Shares
609,700
Previous 366,100 66.54%
Holding current value
$243,880
Previous $190,000 50.53%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.42 - $0.59 $102,312 - $143,724
243,600 Added 66.54%
609,700 $286,000
Q2 2024

Aug 09, 2024

BUY
$0.51 - $0.85 $48,501 - $80,835
95,100 Added 35.09%
366,100 $190,000
Q1 2024

May 13, 2024

BUY
$0.7 - $5.49 $60,129 - $471,591
85,900 Added 46.41%
271,000 $213,000
Q4 2023

Feb 13, 2024

SELL
$1.04 - $2.93 $23,583 - $66,440
-22,676 Reduced 10.91%
185,100 $542,000
Q3 2023

Nov 14, 2023

SELL
$2.04 - $2.54 $63,898 - $79,560
-31,323 Reduced 13.1%
207,776 $470,000
Q2 2023

Aug 11, 2023

BUY
$1.92 - $2.6 $151,678 - $205,397
78,999 Added 49.34%
239,099 $514,000
Q1 2023

May 12, 2023

BUY
$1.15 - $3.17 $24,935 - $68,735
21,683 Added 15.66%
160,100 $354,000
Q4 2022

Feb 13, 2023

SELL
$0.99 - $1.43 $4,636 - $6,696
-4,683 Reduced 3.27%
138,417 $152,000
Q3 2022

Nov 14, 2022

SELL
$1.18 - $2.19 $9,794 - $18,177
-8,300 Reduced 5.48%
143,100 $196,000
Q2 2022

Aug 12, 2022

BUY
$1.28 - $2.23 $50,816 - $88,531
39,700 Added 35.54%
151,400 $263,000
Q1 2022

May 13, 2022

BUY
$1.85 - $4.59 $133,015 - $330,021
71,900 Added 180.65%
111,700 $225,000
Q4 2021

Feb 11, 2022

BUY
$2.33 - $5.74 $13,514 - $33,292
5,800 Added 17.06%
39,800 $178,000
Q3 2021

Nov 12, 2021

BUY
$6.01 - $11.26 $204,340 - $382,840
34,000 New
34,000 $204,000

Others Institutions Holding SPRB

About SPRUCE BIOSCIENCES, INC.


  • Ticker SPRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,560,200
  • Market Cap $9.42M
  • Description
  • Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...
More about SPRB
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.